Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure
NCT01802593 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2015-12-22
Summary
The goal of the present study is to evaluate the best regimen for infliximab monotherapy, and to evaluate if limited combination therapy with IFX and an Immunomodulator for the first 6 months of therapy, in prior Immunomodulator failures, is superior to monotherapy with Immunomodulator cessation from the second infusion, in preventing loss of remission to IFX.
Conditions
Interventions
- DRUG
-
AZATHIOPRINE or METHOTREXATE
Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
- DRUG
-
AZATHIOPRINE or METHOTREXATE
Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2) Thiopurine therapy 2 weeks
Sponsors & Collaborators
-
Prof. Arie Levine
lead OTHER_GOV
Principal Investigators
-
Arie Levine, MD · Pediatric Gastroenterology and Nutrition Unit, The E. Wolfson MC, Tel-Aviv University, Holon, Israel
-
Dan Turner, MD, PhD · Pediatric Gastroenterology and Nutrition Unit, The Hebrew University of Jerusalem, Shaare Zedek MC, Jerusalem, Israel
-
Raanan Shamir, MD · Schneider Childrens Hospital
-
Michal Kori, MD · Kaplan Medical Center
-
Michael Wilshanski, MD · Hadassah Medical Organization
-
Ron Shaoul, MD · Meyer Childrens Hospital Rambam, Haifa, Israel
-
Shlomi Cohen, MD · Tel Aviv Medical Center
-
Batia Weiss, MD · Sheba Medical Center
-
Sarit Peleg, MD · Afula Hospital
-
Baruch Yerushalmi, MD · Soroka University Medical Center
-
Efrat Broide, MD · Asaf Harofe Medical Center
-
Avi On, MD · Poriah Hospital
-
Hussein Chemali, MD · Nazheret Hospital
-
Aharon Lerner, MD · Carmel Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-02-28
- Primary Completion
- 2015-12-31
- Completion
- 2015-12-31
Countries
- Israel
Study Locations
More Related Trials
-
Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
NCT00811174 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
NCT04200365 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
NCT00076726 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
NCT02318082 ·Status: COMPLETED ·Phase: PHASE1
-
Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
NCT00029042 ·Status: TERMINATED ·Phase: PHASE2
-
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT06843408 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)
NCT01066598 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
NCT01818492 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
NCT00589628 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial of Infliximab for Childhood Uveitis
NCT04150770 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
NCT01489956 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Long-term Safety Study of Infliximab (Remicade)
NCT00261976 ·Status: COMPLETED
-
Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03001622 ·Status: COMPLETED ·Phase: PHASE2
-
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
NCT03266653 ·Status: RECRUITING ·Phase: PHASE2
-
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
NCT01905813 ·Status: COMPLETED ·Phase: PHASE1
-
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
NCT04446182 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
NCT07222553 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Clinical Activity of Itolizumab in aGVHD
NCT05823675 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
NCT06263478 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
NCT05825833 ·Status: COMPLETED
-
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
NCT06082323 ·Status: RECRUITING ·Phase: PHASE1
-
Treatment With hOKT3gamma1(Ala-Ala) in T1DM
NCT00806572 ·Status: TERMINATED ·Phase: PHASE2
-
Remicade Infusion Management Program
NCT00723905 ·Status: COMPLETED